Jazz Pharmaceuticals’ (JAZZ) Overweight Rating Reaffirmed at Piper Sandler
Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report ...
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...
FiercePharma4d
Jazz 'active and looking' at M&A deals of 'various sizes' as it wraps up Epidiolex patent fights: execs
Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought ...
StockStory.org on MSN6d
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look ...
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% ...
Jazz Pharmaceuticals price target raised to $200 from $190 at Barclays
Barclays analyst Balaji Prasad raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $200 from $190 and keeps an Overweight rating ...
ETF Daily News2d
Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to Neutral at Cantor Fitzgerald
Cantor Fitzgerald cut shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) from an overweight rating to a neutral rating in a report published on Wednesday, Marketbeat Ratings reports.
Zacks.com on MSN2d
International Markets and Jazz (JAZZ): A Deep Dive for Investors
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Truist Financial Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
Truist Financial analyst Joon Lee maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today. The company’s shares closed ...
Jazz Pharmaceuticals plc Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a good week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders, because the company has just released its latest yearly results, and the shares gained 4.8% to US$143. The result was ...